Cassava Sciences shares are trading higher, rebounding after Friday's drop. The company said Hoau-Yan Wang has had no involvement in the Phase 3 trials of Simufilam.
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences shares are trading higher, rebounding after Friday's drop. The company clarified that Hoau-Yan Wang has had no involvement in the Phase 3 trials of Simufilam.
July 01, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences shares are trading higher after the company clarified that Hoau-Yan Wang has had no involvement in the Phase 3 trials of Simufilam.
The clarification regarding Hoau-Yan Wang's non-involvement in the Phase 3 trials of Simufilam likely alleviated investor concerns, leading to a rebound in Cassava Sciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100